MGMT and glioma: In addition, the detection of tumor protein p53 (TP53) mutations (linked to an inferior prognosis and lower response to chemotherapy) (8), or the assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (useful to guide the use of alkylating agents), represent further molecular biomarkers deserving of careful investigation in diffuse low or high grade gliomas (9).